BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Australian State Triggers Emergency Powers Amid Fuel Crisis - 2Overlooked infertility care should be part of national health services, says WHO
- 3New science points to 4 distinct types of autism
- 4Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- 5The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- Iranian missile hit on Ne'ot Hovav factory leads to fear of chemical leakage
- Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
- Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- Former Peruvian President Pedro Castillo sentenced for conspiracy
- 'Spending more on gas than groceries:' Rising fuel prices drive more San Antonio families to the Food Bank amid Iran war
- Witness the elegance of the cosmic butterfly in a remarkable telescope photo
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- Figure out How to Reveal Stowed away Open Record Rewards
- Tear gas and arrests: Iranian regime continues crackdown on protesters amid economic unrest
